March 25, 2021 07:06 AM EDTUpdated 09:19 AM

FDA adds Guillain-Barré syndrome warning to GlaxoSmithKline’s shingles vaccine

Zachary Brennan

Senior Editor

The FDA late Wednesday sent out a safety communication to explain that while GlaxoSmithKline’s shingles vaccine Shingrix is a safe vaccine, it’s now added a …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA adds Guillain-Barré syndrome warning to GlaxoSmithKline’s shingles vaccine

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

FDA adds Guil­lain-Bar­ré syn­drome warn­ing to Glax­o­SmithK­line’s shin­gles vac­cine

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

FDA adds Guillain-Barré syndrome warning to GlaxoSmithKline’s shingles vaccine